TACKLING CHRONIC LIVER DISEASE
TACKLING CHRONIC LIVER DISEASE
NASH, hepatitis, cirrhosis, liver failure, cancer.
Half a billion people worldwide are at risk unless new therapies are found.
Introducing AI-POWR™
AI-POWR™ combines Artificial Intelligence, Machine Learning, and Deep Learning to decode disease, develop targeted therapies, and to select patients that will respond to Hepion therapies. Learn more >>
About Hepion Pharmaceuticals
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases. The Company’s lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH.